View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 17, 2020

Shionogi commences Phase I/II trial of Covid-19 vaccine candidate

Japanese company Shionogi has commenced Phase I/II clinical trial of a prophylactic Covid-19 vaccine candidate and administered the first dose.

Japanese company Shionogi has commenced Phase I/II clinical trial of a prophylactic Covid-19 vaccine candidate and administered the first dose.

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

The recombinant protein vaccine contains a purified target antigen protein, which is produced using genetic information from the SARS-CoV-2 virus.

Since April, Shionogi has been working on the discovery and development of the recombinant protein vaccine (code No. S-268019), using its subsidiary UMN Pharma’s Baculovirus Expression Vector System technology.

The randomised, double-blind and placebo-controlled study will test multiple doses of the antigen protein and adjuvant in combination.

It has enrolled over 200 Japanese adult participants.

The safety, tolerability and immunogenicity of two doses of the vaccine, given three weeks apart, will be evaluated to determine the optimal dose.

Flash reports from the trial are anticipated to be obtained from the February end next year.

Based on these results and the global pandemic situation, the company will hold discussions with the Japanese Ministry of Health, Labor and Welfare, Pharmaceuticals and Medical Devices Agency (PMDA) and other organisations on further clinical studies.

In a separate development, Medigen Vaccine Biologics has sought permission from Taiwan’s Food and Drug Administration (FDA) to initiate Phase II clinical trials of its Covid-19 vaccine.

Focus Taiwan quoted Medigen as saying that all subjects in its Phase I trial had received the two doses of the vaccine, allowing researchers to obtain results on its safety and ability to elicit an immune response.

The company intends to test the vaccine’s efficacy on 3,700 volunteers.

Medigen’s recombinant protein vaccine, MVC-COV1901 is developed jointly with the US National Institutes of Health (NIH)

Medigen is the third firm in Taiwan to seek approval for testing the efficacy of its product on a larger scale, following Adimmune and United Biomedical.

The company received funding worth NT$472.19m ($16.78m) from Taiwan’s government to develop the vaccine.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena